Nestle Health Science agreed to acquire Aimmune Therapeutics for $34.50/share in cash, ~$2.6B fully-diluted equity value (174% premium to 8/28 close). Brought Palforzia, the first FDA-approved peanut allergy oral immunotherapy, into Nestle Health Science. NHSc's prior ~$473M, 25.6% stake in Aimmune was rolled up.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Terminated
Assessment window: 5yr post-close.
Key facts
AnnouncedAug 31, 2020
ClosedOct 14, 2020
Deal value$2.6B
Deal typeAcquisition/Merger
Therapeutic areaPeanut allergy in children/adolescents 4-17
IndicationsPeanut allergy in children/adolescents 4-17